1. |
Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008:a systematic analysis of disability-adjusted lifeyears in 12 world regions. Lancet, 2012, 380(9856) :1840-1850.
|
2. |
Berghmans T, Pasleau F, Paesmans M, et al. Surrogate markers predicting overall survival for lung cancer:ELCW P recommendations. Eur Respir J, 2012, 39(1) :9-28.
|
3. |
Non-Small Cell Lung Cancer Collaborative Group. Chemotherapyinnon-smallcelllungcancer:ameta-analysisusingupdateddataon individual patients from 52 randomised clinical trials. BMJ, 1995, 311(7010) :899-909.
|
4. |
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer. Available at: http://www.nccn.com.2013.
|
5. |
Ihbe-Heffinger A, Paessens B, Berger K, et al. The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care-an observational analysis on non-smallcell lung cancer patients. Support Care Cancer, 2013, 21(6) :1665-1675.
|
6. |
Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV nonsmall cell lung cancer:Diagnosis and management of lung cancer, 3rd ed:American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl):e341S-368S.
|
7. |
NICE. The diagnosis and treatment of lung cancer. 2011. Available at:http://guidance.nice.org.uk/cg121.
|
8. |
D'Addario G, Felip E. Non-small-cell lung cancer:ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009, 20 (Suppl 4) :68-70.
|
9. |
De Marinis F, Rossi A, Di MM, et al. Treatment of advanced nonsmall-cell lung cancer:Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer, 2011, 73(1) :1-10.
|
10. |
Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 2007, 7:169-181.
|
11. |
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at:http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
|
12. |
Cochrane Handbook for Systematic Reviews of Interventions 5.2. The Cochrane Collaboration, 2009.
|
13. |
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25) :2380-2388.
|
14. |
Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist, 2012, 17(6) :863-870.
|
15. |
Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) . Ann Oncol, 2013, 24(1) :54-59.
|
16. |
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) :an open label, randomised phase 3 trial. Lancet Oncol, 2013, 11(2) :121-128.
|
17. |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10) :947-957.
|
18. |
Thongprasert S, Duffield E, Saijo N, et al. Health-related qualityof-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol, 2011, 6(11) :1872-1880.
|
19. |
Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011, 29(21) :2866-2874.
|
20. |
Lee Y, Kim SH, Han JY, et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol, 2012,.
|
21. |
(12) :2009-2016.
|
22. |
Han JY, Park K, Kim SW, et al. First-SIGNAL:First-Line SingleAgent Iressa Versus Gemcitabine and Cisplatin Trial in NeverSmokers With Adenocarcinoma of the Lung. J Clin Oncol, 2012, 30(10) :1122-1128.
|
23. |
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802) :a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8) :735-742.
|
24. |
Chen G, Feng J, Zhou C, et al. Quality of lif e (QoL) analyses from OPTIMAL(CTONG-0 802) , a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol, 2013, 24(6) :1615-1622.
|
25. |
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3) :239-246.
|
26. |
Gridelli C, Rossi A. EURTAC first-line phase III randomized study in advanced non-small cell lung cancer:Erlotinib works also in European population. J Thorac Dis, 2012, 4(2) :219-220.
|
27. |
Gridelli C, Ciardiello F,Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced nonsmall-cell lung cancer:the TORCH randomized trial. J Clin Oncol, 2012, 30(24) :3002-3011.
|
28. |
Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol, 2008, 26(6) :863-869.
|
29. |
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27) : 3327-3334.
|
30. |
Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3:a phase III study of afatinib or cisplatin/ pemetrexed in patientswith advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31(27) :3342-3350.
|
31. |
Estimated cancer Incidence, Mortality, Prevalence and Disabilityadjusted life years (DALYs) world wide in 2012. Available at:http://globocan.iarc.fr/.
|
32. |
Pakkala S, Ramalingam SS. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small cell lung cancer therapy. Clin Lung Cancer, 2009, 10(Suppl 1) :S17-23.
|
33. |
Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage nonsmall-cell lung cancer (FASTACT-2) :a randomised, double-blind trial. Lancet Oncol, 2013, 14(8) :777-786.
|
34. |
郭珑华,吴一龙,周清.非小细胞肺癌表皮生长因子受体基因突变 的异质性. 肿瘤研究与临床, 2012, 24(9) :577-588.
|